Piper Sandler Increases Biogen (NASDAQ:BIIB) Price Target to $177.00

Biogen (NASDAQ:BIIB) had its price target increased by investment analysts at Piper Sandler from $157.00 to $177.00 in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage presently has a “neutral” rating on the biotechnology company’s stock. Piper Sandler’s target price indicates a potential downside of 6.34% from the company’s current price.

A number of other research analysts have also recently issued reports on the company. Guggenheim lifted their price objective on Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a report on Monday. Robert W. Baird cut their price target on shares of Biogen from $255.00 to $250.00 in a report on Friday, October 31st. Truist Financial boosted their price target on shares of Biogen from $142.00 to $190.00 and gave the company a “hold” rating in a research report on Thursday, January 8th. Mizuho raised their price objective on shares of Biogen from $177.00 to $207.00 and gave the stock an “outperform” rating in a report on Thursday, January 8th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Biogen in a research note on Tuesday, January 13th. Thirteen analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the stock. According to MarketBeat, Biogen has an average rating of “Hold” and a consensus target price of $207.81.

Biogen Stock Down 2.5%

NASDAQ BIIB opened at $188.99 on Monday. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The stock’s 50 day moving average is $177.44 and its two-hundred day moving average is $157.89. The company has a market capitalization of $27.74 billion, a price-to-earnings ratio of 21.45, a PEG ratio of 1.55 and a beta of 0.16. Biogen has a 1-year low of $110.04 and a 1-year high of $202.41.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.Biogen’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities analysts forecast that Biogen will post 15.83 earnings per share for the current fiscal year.

Insider Activity at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.18% of the stock is currently owned by corporate insiders.

Institutional Trading of Biogen

A number of institutional investors have recently bought and sold shares of BIIB. Empowered Funds LLC boosted its position in shares of Biogen by 64.9% in the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares during the last quarter. Focus Partners Wealth lifted its stake in Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after buying an additional 6,436 shares during the period. Sivia Capital Partners LLC bought a new position in Biogen during the second quarter worth about $216,000. Blair William & Co. IL boosted its holdings in Biogen by 11.8% during the second quarter. Blair William & Co. IL now owns 14,844 shares of the biotechnology company’s stock worth $1,864,000 after buying an additional 1,561 shares during the last quarter. Finally, Callan Family Office LLC acquired a new position in shares of Biogen during the 2nd quarter worth about $308,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and updated guidance — Biogen reported Q4 results and FY guidance that topped expectations (EPS and revenue beats; FY2026 EPS range of 15.25–16.25), a key driver for recent analyst upgrades and higher targets. Article Title
• Positive Sentiment: Leqembi subcutaneous BLA gets priority review — The biologics license application for a subcutaneous formulation of Leqembi (lecanemab) was designated for priority review, which could materially expand the Alzheimer’s franchise if approved. Article Title
• Positive Sentiment: Multiple bullish analyst moves lift upside — Several firms raised price targets and/or maintained Buy ratings after the results and pipeline updates (Goldman Sachs PT raised to $231; RBC to $233; HC Wainwright to $228; Canaccord and others also raised targets), supporting multi-quarter upside expectations. Article Title
• Neutral Sentiment: Pipeline diversification headlines (lupus, SMA) — Management and coverage note advancing programs beyond Alzheimer’s, which improves long-term growth optionality but will take time to materialize. Article Title
• Neutral Sentiment: Mixed analyst stances — Several shops raised price targets but kept neutral/hold ratings (Citigroup, Piper Sandler, Wedbush, Truist), indicating disagreement on valuation even after beats. Article Title
• Neutral Sentiment: Short-interest report appears unreliable — A reported “significant increase” shows zero shares in the feed (data inconsistent); no clear short-covering pressure signaled. (internal short-interest entry)
• Negative Sentiment: Ongoing franchise pressure and execution risk — Coverage notes that legacy multiple sclerosis (MS) franchise pressures and execution on expanding Leqembi access/commercial scale remain risks that could cap near-term upside. Article Title

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.